leisure time -WSS

leisure time

author：explore 2025-10-06 07:54:32 - browse：42168

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

I have one more, admittedly braggy thing to say about last week’s STAT Breakthrough Summit West in San Francisco. Of course we curated an incredible roster of influential industry leaders to speak on stage. That’s what STAT does. But just as remarkable were the health care and health tech A-Listers who just showed up as summit attendees to listen and learn from their peers — like 23AndMe’s Anne Wojcicki. Please join us in San Francisco next year, or better yet, register for our next summit in Boston, Oct. 16-17.

I’m back in Boston from San Francisco, but flying out again next week, this time to Chicago for the annual meeting of the American Society of Clinical Oncology. How can we be knocking on June, already?

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： PBM executives asked to testify by House panel

WSS

In shift, Texas to cover initial consult for Afghan baby's gene therapy

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Study suggests new cause of Down syndrome: cells linked to aging

Boston Scientific acquires urology company Axonics for $3.7 billion

Merck to acquire Harpoon Therapeutics for $680 million

Gene therapy denied for Afghan refugee whose father aided U.S.

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

BIO to announce reorganization, senior leaders expected to depart

At least 13 dead in Texas as scorching temps continue

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Cancer drug shortages should be causing more outrage

Ascension's ugly legal battle over care for poor patients in Texas

Dobbs anniversary: the lost opportunity of abortion as health care

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Hepatitis C has a cure — but many Americans still lack access to it

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

hotspot

The creative science of coining drug names

Hospital chaplains balance Covid safety with patients’ spiritual needs

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Profiling embryos to choose those with higher IQs is almost a reality

BIO to announce reorganization, senior leaders expected to depart

hotspot

hotspot

explore

focus